Resultados da pesquisa - Shakeel Modak

Refinar resultados
  1. 1
    Anti-GD2 immunotherapy for neuroblastoma

    Anti-GD2 immunotherapy for neuroblastoma Por Sameer Farouk Sait, Shakeel Modak

    Publicado em 2017
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Norepinephrine Transporter as a Target for Imaging and Therapy

    Norepinephrine Transporter as a Target for Imaging and Therapy Por Neeta Pandit‐Taskar, Shakeel Modak

    Publicado em 2017
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Management of desmoplastic small round cell tumor

    Management of desmoplastic small round cell tumor Por Andrea Hayes‐Jordan, Michael P. LaQuaglia, Shakeel Modak

    Publicado em 2016
    Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  4. 4
    Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma

    Sensitivity of Surveillance Studies for Detecting Asymptomatic and Unsuspected Relapse of High-Risk Neuroblastoma Por Brian H. Kushner, Kim Kramer, Shakeel Modak, Nai-KongV. Cheung

    Publicado em 2009
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    Successful Multifold Dose Escalation of Anti-G<sub>D2</sub> Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study

    Successful Multifold Dose Escalation of Anti-G<sub>D2</sub> Monoclonal Antibody 3F8 in Patients With Neuroblastoma: A Phase I Study Por Brian H. Kushner, Kim Kramer, Shakeel Modak, Nai‐Kong V. Cheung

    Publicado em 2011
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma

    Irinotecan Plus Temozolomide for Relapsed or Refractory Neuroblastoma Por Brian H. Kushner, Kim Kramer, Shakeel Modak, Nai‐Kong V. Cheung

    Publicado em 2006
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma

    Ototoxicity from high‐dose use of platinum compounds in patients with neuroblastoma Por Brian H. Kushner, Amy Budnick, Kim Kramer, Shakeel Modak, Nai‐Kong V. Cheung

    Publicado em 2006
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study

    Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study Por Shakeel Modak, Brian H. Kushner, Ellen M. Basu, Stephen S. Roberts, Nai‐Kong V. Cheung

    Publicado em 2017
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission

    Phase I Trial of a Bivalent Gangliosides Vaccine in Combination with β-Glucan for High-Risk Neuroblastoma in Second or Later Remission Por Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Kim Kramer, Govind Ragupathi, Nai‐Kong V. Cheung

    Publicado em 2014
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    Humanized 3F8 Anti-G<sub>D2</sub>Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma

    Humanized 3F8 Anti-G<sub>D2</sub>Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma Por Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts, Nai‐Kong V. Cheung

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-<i>Cis</i>-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

    Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-<i>Cis</i>-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblast... Por Nai‐Kong V. Cheung, Irene Y. Cheung, Brian H. Kushner, Irina Ostrovnaya, Elizabeth Chamberlain, Kim Kramer, Shakeel Modak

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma

    Local Control With 21-Gy Radiation Therapy for High-Risk Neuroblastoma Por Dana L. Casey, Brian H. Kushner, Nai‐Kong V. Cheung, Shakeel Modak, Michael P. LaQuaglia, Suzanne L. Wolden

    Publicado em 2016
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  13. 13
    Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub>immunotherapy and isotretinoin: a prospective Phase II study

    Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G<sub>D2</sub>immunotherapy and isotretinoin: a prospective Phase II s... Por Brian H. Kushner, Irina Ostrovnaya, Irene Y. Cheung, Deborah Kuk, Kim Kramer, Shakeel Modak, Karima Yataghene, Nai‐Kong V. Cheung

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors

    Thiotepa-Based High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Recurrent or Progressive CNS Germ Cell Tumors Por Shakeel Modak, Sharon L. Gardner, Ira J. Dunkel, Casilda Balmaceda, Marc K. Rosenblum, Douglas C. Miller, Steven Halpern, Jonathan L. Finlay

    Publicado em 2004
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: <scp>L</scp>ong‐term progression‐free survival of patients with resistant neuroblastoma

    A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: <scp>L</scp>ong‐term progression‐free survival of patients with resistant neuroblastoma Por Brian H. Kushner, Nai‐Kong V. Cheung, Shakeel Modak, Oren J. Becher, Ellen M. Basu, Stephen S. Roberts, Kim Kramer, Ira J. Dunkel

    Publicado em 2016
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  16. 16
    Key role for myeloid cells: Phase II results of anti‐G<sub>D2</sub> antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblastoma

    Key role for myeloid cells: Phase II results of anti‐G<sub>D2</sub> antibody 3F8 plus granulocyte‐macrophage colony‐stimulating factor for chemoresistant osteomedullary neuroblasto... Por Nai‐Kong V. Cheung, Irene Y. Cheung, Kim Kramer, Shakeel Modak, Deborah Kuk, Neeta Pandit‐Taskar, Elizabeth Chamberlain, Irina Ostrovnaya, Brian H. Kushner

    Publicado em 2014
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression

    Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression Por Irene Y. Cheung, Nai‐Kong V. Cheung, Shakeel Modak, Audrey Mauguen, Yi Feng, Ellen M. Basu, Stephen S. Roberts, Govind Ragupathi, Brian H. Kushner

    Publicado em 2020
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin

    Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin Por Brian H. Kushner, Irina Ostrovnaya, Irene Y. Cheung, Deborah Kuk, Shakeel Modak, Kim Kramer, Stephen S. Roberts, Ellen M. Basu, Karima Yataghene, Nai‐Kong V. Cheung

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Treatment and outcome of adult‐onset neuroblastoma

    Treatment and outcome of adult‐onset neuroblastoma Por Maya Suzuki, Brian H. Kushner, Kim Kramer, Ellen M. Basu, Stephen S. Roberts, William J. Hammond, Michael P. LaQuaglia, Suzanne L. Wolden, Nai‐Kong V. Cheung, Shakeel Modak

    Publicado em 2018
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment

    Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment Por Nidale Tarek, Jean-Benoît Le Luduec, Meighan M. Gallagher, Junting Zheng, Jeffrey M. Venstrom, Elizabeth Chamberlain, Shakeel Modak, Glenn Heller, Bo Dupont, Nai‐Kong V. Cheung, Katharine C. Hsu

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: